Anixa Biosciences Inc

NASDAQ ANIX

Data sourced from

and

Download Data

Anixa Biosciences Inc Cash Per Share 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending January 31, 2024: -94.80%

Anixa Biosciences Inc Cash Per Share 1 year YoY Change (%) is -94.80% for the Trailing 12 Months (TTM) ending January 31, 2024, a -162.89% change year over year. The cash per share represents the amount of cash available to each outstanding share of common stock. It is calculated by dividing the total cash by the weighted average number of shares outstanding. This metric provides insight into the cash position of the company on a per-share basis and can be used to evaluate the company's liquidity and ability to distribute cash to shareholders. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Anixa Biosciences Inc Cash Per Share for the Trailing 12 Months (TTM) ending January 31, 2023 was 0.61, a -36.06% change year over year.
Anixa Biosciences Inc Cash Per Share for the Trailing 12 Months (TTM) ending January 31, 2022 was 0.95, a 239.59% change year over year.
Anixa Biosciences Inc Cash Per Share for the Trailing 12 Months (TTM) ending January 31, 2021 was 0.28, a 56.44% change year over year.
Anixa Biosciences Inc Cash Per Share for the Trailing 12 Months (TTM) ending January 31, 2020 was 0.18, a -6.26% change year over year.

NASDAQ: ANIX

Anixa Biosciences Inc

CEO	Dr. Amit Kumar Ph.D.
IPO Date	Jan. 1, 1987
Location	United States
Headquarters	3150 Almaden Expressway, San Jose, CA, United States, 95118
Employees	4
Sector	Healthcare
Industry	Biotechnology

Description

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Key trends